Scope and Claims Analysis of U.S. Patent 7,465,462 (Fluvoxamine Multiparticulate Controlled-Release SSRI) and the U.S. Patent Landscape
U.S. Patent 7,465,462 claims a multiparticulate, oral controlled-release fluvoxamine (SSRI) composition built on inert “non-pareil” cores with (1) an SSRI layer containing fluvoxamine or salts and (2) a rate-controlling polymer coating defined by polymeric acrylate/methacrylate “lacquer” systems. The claims hinge on the combination of two particle populations with different coating amounts and a tightly defined USP paddle dissolution profile in 0.05 M phosphate buffer pH 6.8 over ~12+ hours. Downstream claim coverage expands into method-of-use for depression/OCD and into in vivo exposure ranges (AUC0-∞) as performance gates.
What claims are in U.S. Patent 7,465,462 and what do they require for infringement?
Answer: Independent coverage requires a specific architecture (two populations of coated multiparticulates), specific materials (fluvoxamine or salt on a layered core; rate-controlling polymeric acrylate/methacrylate lacquer over the SSRI layer), and specific performance in vitro (USP II paddle dissolution windows at pH 6.8) for controlled release of fluvoxamine over not less than ~12 hours.
What is the claimed product structure (core, SSRI layer, rate-controlling lacquer)?
Across claims 1, 9, 17, 25, and 33 (with parallel dependent claim sets), each particle must contain:
- Inert non-pareil core (multiparticulate seed).
- SSRI layer disposed over the core, where the SSRI is fluvoxamine or a pharmaceutically acceptable salt.
- Rate-controlling coating disposed over the fluvoxamine layer, where the coating is:
- polymeric acrylate lacquer,
- polymeric methacrylate lacquer, or
- a mixture of acrylate and methacrylate lacquers.
Key structural requirement: the overall composition is multiparticulate and includes two quantities of particles with different amounts of the rate-controlling lacquer across the two populations.
What is the performance “gate” in the independent claims?
The independent claims define controlled release using in vitro dissolution measured with:
- USP Type II (paddle) apparatus
- per USP XXII
- 0.05 M phosphate buffer, pH 6.8
The claims specify multiple timepoint windows that collectively define a dissolution curve, not merely a single endpoint.
How does claim scope vary across the different independent claim sets?
The independent claims are structurally similar but use different dissolution acceptance windows. Practically, this means infringement can occur under multiple claim “tracks” if a formulation’s dissolution profile fits the selected window set.
Key dissolution window themes by independent claim group:
Claim 1 dissolution profile (0.5–6 hour emphasized)
- ≤15% released at 0.5 hr
- ≤25% released at 1 hr
- 20–75% released at 2 hr
- ≥75% released at 4 hr
- ≥85% released at 6 hr
- controlled release period: not less than ~12 hours (stated as a period requirement even though this claim’s enumerated dissolution windows end at 6 hr)
Claim 9 dissolution profile (4–12 hour emphasized)
- ≤20% at 4 hr
- ≤45% at 6 hr
- 45–80% at 8 hr
- ≥70% at 10 hr
- ≥80% at 12 hr
Claim 17 dissolution profile (1–12 hour distribution)
- ≤20% at 1 hr
- ≤60% at 2 hr
- ≥20% at 4 hr
- ≥35% at 6 hr
- ≥50% at 8 hr
- ≥70% at 10 hr
- ≥75% at 12 hr
Claim 25 dissolution profile (1–12 hour with broader windows)
- ≤20% at 1 hr
- ≤45% at 2 hr
- 20–70% at 4 hr
- 35–85% at 6 hr
- ≥50% at 8 hr
- ≥70% at 10 hr
- ≥75% at 12 hr
Claim 33 dissolution profile (2–22 hour endpoints)
- ≤50% at 2 hr
- ≥35% at 6 hr
- ≥80% at 22 hr
(Still anchored by “not less than about 12 hours” in the general controlled-release requirement.)
What dependent claims narrow the polymer/coating definition?
Dependent claims lock the coating composition more tightly:
-
Claims 2–5 / 10–13 / 18–21 / 26–29 / 34–37: choose among
- polymeric acrylate lacquer,
- polymeric methacrylate lacquer,
- mixed acrylate/methacrylate lacquer,
- acrylic resin copolymer with low quaternary ammonium group content (acrylic + methacrylic acid esters; “low content” is a qualitative boundary but is included as a structural limitation).
-
Claims 6–7 / 14–15 / 22–23 / 30–31 / 38–39: define an ammonio methacrylate lacquer + plasticizer coating and give a combined mass % range in the membrane coating:
- total coating of lacquer + plasticizer: ~4% to ~15% by weight of the particle
- and selected discrete values for first/second particle quantity coating amount: 4, 6, 8, 10, 12, 15%
Where do in vivo exposure limits show up in claim scope?
The specification-like performance requirement is embedded as dependent claims:
- Claims 8, 16, 24, 32, 40: require that controlled release results in serum exposure:
- AUC0-∞ ~128 to ~1,175 ng·h/mL following a single application.
This is a second axis of proof beyond dissolution. A competing product that hits the in vitro dissolution may still avoid claims if exposure falls outside the defined AUC window, depending on how courts construe whether the AUC range is a required structural/performance feature.
What method-of-use coverage is claimed?
- Claims 41–45: “treatment” of depression or obsessive compulsive disorder (conditions “treatable with an SSRI”) by administering the multiparticulate controlled-release fluvoxamine composition. These method claims re-state the product architecture and controlled-release dissolution windows (same dissolution acceptance gates as independent claim tracks).
Practical implication: if a product is found to infringe product claims, method-of-use claims generally become easier to align with clinical use and label/indication arguments, though actual litigation will depend on evidence of use.
How broad is the claim coverage: “lacquer-controlled release” and “two particle populations” as core limiting elements?
Answer: The claim set is broad on the SSRI identity (fluvoxamine or salts) and polymer family (acrylate/methacrylate lacquers), but narrow on the combination of:
- multiparticulate with inert non-pareil cores,
- two particle populations with differing lacquer amounts,
- specific dissolution timepoint windows at pH 6.8 using USP II paddle,
- optional but material dependence on lacquer/plasticizer composition details and AUC range.
Key limiting elements likely to determine infringement outcomes
- Two-quantity particle population requirement
- The composition must include two particle populations with different lacquer amounts. A single-population system may be designed to avoid this element if it is not equivalently “two quantities” under claim construction.
- Rate-controlling coating identity
- The claim is limited to polymeric acrylate/methacrylate lacquers (or mixtures), plus a defined alternative dependent set for ammonio methacrylate lacquer + plasticizer.
- Dissolution protocol and acceptance windows
- Using USP II paddle, phosphate buffer pH 6.8, and the stated timepoints. Even if a formulation is similar, missing one window can be fatal for that claim track.
- Dissolution window endpoints differ across the independent claim sets
- This creates multiple “ways in,” but also multiple ways to design around by shifting dissolution curves to fall outside all tracks.
What is the likely patent strategy embedded in the claim drafting?
Answer: The claims are drafted to create an overlapping matrix of infringement paths:
- multiple independent claims with different dissolution window patterns,
- dependent claims that tighten polymer chemistry and coating composition,
- optional AUC performance gates,
- and method-of-use claims that preserve enforceability even if a product is used in labeled indications.
Why are multiple dissolution window patterns used?
They likely correspond to multiple embodiments and process targets (different coating amounts, different lacquer types, different polymer/plasticizer compositions). A competitor attempting to redesign the formulation can target different “failure modes”:
- move early dissolution earlier or later,
- change the mid-timepoint fraction released,
- or alter late release so it misses ≥ thresholds at 10–12 hours or > thresholds at 22 hours.
Why are “two coating amounts” across two particle populations central?
This element supports claims that cover graded-release systems without requiring specific coating weights per se unless dependent claims are invoked. It also supports a common manufacturing strategy: blending or producing two populations with different membrane deposition levels.
How to map the claim set to potential design-around strategies (engineering and legal risk)
Answer: The claim structure implies that design-around risk is primarily dissolution-window compliance and the “two particle populations with different lacquer amounts” architecture.
High-risk design regions for generic or follow-on formulations
- Formulations using fluvoxamine layered on inert cores and coated with acrylate/methacrylate lacquers to achieve ~12+ hour controlled release are structurally within the claimed design space.
- Systems that intentionally produce two populations (two coating levels) to tune dissolution are likely to match the two-quantity requirement.
Likely design-around approaches
-
Avoid the “two quantities” element
- Use a single particle population or a design where coating variation is not captured as “two quantities” (this is claim-construction sensitive and evidence-driven).
-
Change coating chemistry outside the claimed lacquer family
- Use different controlled-release polymers (e.g., non-lacquer systems) so the coating is not “polymeric acrylate/methacrylate lacquer” or the ammonio methacrylate + plasticizer combination under dependent claims.
-
Shift dissolution curve outside all independent claim window tracks
- Target violations such as:
- early release exceeding ≤ thresholds (e.g., >15% at 0.5 hr or >20% at 1 hr),
- midtime window mismatch (e.g., falling outside 20–75% at 2 hr or outside 35–85% at 6 hr),
- late-time mismatch (failing ≥70% at 10 hr or ≥80% at 12 hr, or missing ≥80% at 22 hr in the longer track).
-
Use AUC outside the claimed dependent ranges
- If a product hits dissolution windows but produces clinically different exposure, AUC-dependent claims could be avoided (again, evidence dependent).
What “scope” does the patent likely cover around competitors?
Answer: Based on the claim limits, the patent targets a specific formulation archetype: multiparticulates with layered fluvoxamine and lacquer-controlled membranes tuned by blending two coated populations to hit specific dissolution curves in pH 6.8 phosphate using USP II.
What competitor products would likely be at risk?
- Any oral once-daily/controlled-release fluvoxamine product using acrylic/methacrylic lacquer-type membranes for multiparticulates with tunable dissolution via differing coating levels.
- If such products also match the “two populations” and dissolution windows, the infringement risk is high.
What competitor products may be lower risk?
- Immediate release, or controlled-release built on different release mechanisms and different membrane polymer classes.
- Controlled-release that uses uniform coating levels without a two-population blend.
- Products that meet dissolution but use materials not characterized as the claimed lacquers and do not meet the dependent polymer/plasticizer definitions.
Key Takeaways
- U.S. Patent 7,465,462 claims a specific multiparticulate controlled-release fluvoxamine architecture: inert non-pareil cores + fluvoxamine layer + acrylate/methacrylate lacquer rate-controlling membrane.
- Core limiting element: the composition includes two particle populations with different lacquer coating amounts.
- Primary infringement test: whether the product’s USP II paddle dissolution in 0.05 M phosphate buffer pH 6.8 falls within one or more of the enumerated timepoint windows up to 12 hours (and in one track up to ~22 hours).
- Secondary gate: dependent claims add tighter coating chemistry (ammonio methacrylate lacquer + plasticizer and defined membrane wt%) and AUC0-∞ exposure windows.
- Method-of-use claims cover treating depression and OCD by administering the infringing controlled-release composition.
FAQs
1) Does U.S. Patent 7,465,462 require two distinct particle populations or just two different coating amounts somewhere in the batch?
The claims require a composition comprising two quantities of particles where the rate-controlling lacquer coating amount differs between those two quantities.
2) What dissolution test parameters matter most for infringement?
The claims specify USP Type II paddle, USP XXII, 0.05 M phosphate buffer, pH 6.8, and multiple discrete timepoints tied to percentage released thresholds.
3) Which polymer systems are explicitly covered?
The coating is limited to polymeric acrylate lacquer, polymeric methacrylate lacquer, or mixtures of those. Dependent claims further cover acrylic resin copolymers with low quaternary ammonium groups and ammonio methacrylate lacquer + plasticizer formulations at defined wt% ranges.
4) Are AUC exposure ranges required for all claims?
No. The AUC0-∞ range appears in dependent claims (8, 16, 24, 32, 40). Independent claims focus on the controlled-release period and the dissolution windows.
5) How do the different independent claim tracks change infringement risk?
Each independent claim uses different dissolution timepoint acceptance windows (some emphasize early timepoints like 0.5–2 hr, others emphasize late timepoints like 10–12 hr, and one track includes a ~22 hr endpoint). A product could infringe if it matches any track, so design-around should test against all window sets.
